

[Skip to Main Content](#)

Login to your account

Email/Username

Password

[Show](#)

[Forgot password?](#)

☒ Remember me

Don't have an account?

[Create a Free Account](#)

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email*

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

[Cancel](#)

 Advertisement

 [Lung Cancer](#)

[Close](#)

- [Home](#)
- [Articles and Issues](#)
 - [Back](#)
 - [Articles in Press](#)
 - [Current Issue](#)
 - [List of Issues](#)
- [For Authors](#)
 - [Back](#)
 - [About Open Access](#)
 - [Author Information](#)
 - [Permissions](#)
 - [Researcher Academy](#)
 - [Submit a Manuscript](#)
- [Journal Info](#)
 - [Back](#)
 - [About Open Access](#)
 - [About the Journal](#)
 - [Abstracting/Indexing](#)
 - [Advertising Information](#)
 - [Career Opportunities](#)
 - [Contact Information](#)
 - [Editorial Board](#)
 - [Pricing](#)
 - [New Content Alerts](#)
- [Subscribe](#)

- [Society Info](#)
 - [Back](#)
 - [International Lung Cancer Consortium \(ILCCO\)](#)
 - [European Thoracic Oncology Platform \(ETOP\)](#)
 - [British Thoracic Oncology Group \(BTOG\)](#)
- [More Periodicals](#)
 - [Back](#)
 - [Find a Periodical](#)
 - [Go to Product Catalog](#)

Search for...

Go search

All Content



[Advanced Search](#)[Save search](#)

Please enter a term before submitting your search.

[Ok](#)

- [Submit Article](#)
- [Log in](#)
- [Register](#)
- [Log in](#)
 - [Submit Article](#)
 - [Log in](#)
- [Subscribe](#)
- [Claim](#)

Full length article| [Volume 53, ISSUE 3](#), P273-284, September 01, 2006

- [Purchase](#)
 - [Academic and Personal](#)
 - [Corporate R&D Professionals](#)
- [Subscribe](#)
- [Save](#)
 - [Add To Online Library](#) Powered By Mendeley
 - [Add To My Reading List](#)
 - [Export Citation](#)
 - [Create Citation Alert](#)
- [Share](#)

Share on

 - Email
 - Twitter
 - Facebook
 - Linked In
 - Sina Weibo
- [more](#)
 - [Reprints](#)
 - [Request](#)
- [Top](#)

In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2

- [Katherine M. Finan](#)

Katherine M. Finan

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

- [Greg Hodge](#)

Greg Hodge

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

Department of Haematology, Women's and Children's Hospital, Adelaide, South Australia 5000, Australia

University of Adelaide, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

- [Ann M. Reynolds](#)

Ann M. Reynolds

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

- [Sandra Hodge](#)

Sandra Hodge

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

- [Mark D. Holmes](#)

Mark D. Holmes

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

University of Adelaide, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

- [Andrew H. Baker](#)

Andrew H. Baker

Affiliations

University of Glasgow, Glasgow, UK

[Search for articles by this author](#)

- [Paul N. Reynolds](#)

Paul N. Reynolds

Correspondence

Corresponding author. Tel.: +61 8 8222 5376; fax: +61 8 8222 5957.

[Contact](#)

Affiliations

Department of Thoracic Medicine and Lung Research Laboratory, Royal Adelaide Hospital and Hanson Institute, Adelaide, South Australia 5000, Australia

University of Adelaide, Adelaide, South Australia 5000, Australia

[Search for articles by this author](#)

DOI: <https://doi.org/10.1016/j.lungcan.2006.06.006>

[In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2](#)



Summary

Matrix metalloproteinases (MMPs) are essential for extracellular matrix (ECM) breakdown and repair, and have been implicated in the development of metastases. TIMP-3 was initially identified as a potent inhibitor of MMPs, however it also has several properties that are unique and not related to its ability to abrogate MMPs. We studied the effects of overexpression of tissue inhibitor of metalloproteinases-3 (TIMP-3) on lung cancer cells and explored the mechanisms involved in apoptosis-induction in susceptible cells and subsequently, the therapeutic effect in vivo. Overexpression of TIMP-3 resulted in apoptosis of A549 lung cancer cells and AdCMVTIMP3 up-regulated the expression of p53, Fas ligand, TNFR1 and TNFR2 on these cells. Adenoviral delivery of TIMP-3 gene inhibited the growth of pre-established A549 tumours in Balb/c nude mice, and was associated with a greater therapeutic effect than either TIMP-1 or -2 gene delivery. There was no evidence of increased hepatic toxicity following the delivery of TIMP-3 either from intra-tumoural or intravenous injection. Thus, at least in cells showing in vitro susceptibility, TIMP-3 gene therapy offers a therapeutic advantage over TIMPs 1 and 2. These findings establish the potential of adenoviral gene delivery of TIMP3 as a therapeutic agent for selected lung cancers.

Keywords

- [Lung cancer](#)
- [Gene therapy](#)
- [TIMP-3](#)
- [Apoptosis](#)
- [A549 lung cancer cell line](#)
- [Subcutaneous lung cancer nodules](#)

To read this article in full you will need to make a payment

Purchase one-time access:

[Academic and Personal](#)[Corporate R&D Professionals](#)

- One-time access price info

Subscribe:

[Subscribe to Lung Cancer](#)

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

References

1.
 - Fong K.M.
 - Sekido Y.
 - Gazdar A.F.
 - Minna J.D.

Lung cancer. 9: Molecular biology of lung cancer: clinical implications.
Thorax. 2003; 58: 892-900

[View in Article](#)

- [Scopus \(113\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

2. ◦ American Cancer Society
Cancer facts and figures.
American Cancer Society, Atlanta 2005

[View in Article](#)

- [Google Scholar](#)

3. ◦ Kahari V.M.
◦ Saarialho-Kere U.

Matrix metalloproteinases and their inhibitors in tumour growth and invasion.

Ann Med. 1999; 31: 34-45

[View in Article](#)

- [Scopus \(348\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

4. ◦ Chambers A.F.
◦ Matrisian L.M.

Changing views of the role of matrix metalloproteinases in metastasis.

J Natl Cancer Inst. 1997; 89: 1260-1270

[View in Article](#)

- [Scopus \(1413\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

5. ◦ Baker A.H.
◦ Zaltsman A.B.
◦ George S.J.
◦ Newby A.C.

Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

J Clin Invest. 1998; 101: 1478-1487

[View in Article](#)

- [Scopus \(408\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

6. ◦ Zucker S.
◦ Cao J.
◦ Chen W.T.

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Oncogene. 2000; 19: 6642-6650

[View in Article](#)

- [Scopus \(488\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

7. ◦ Bachman K.E.
◦ Herman J.G.
◦ Corn P.G.
◦ Merlo A.
◦ Costello J.F.

- Cavenee W.K.
- et al.

Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Cancer Res. 1999; 59: 798-802

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

8.
 - Yu W.H.
 - Yu S.
 - Meng Q.
 - Brew K.
 - Woessner Jr., J.F.

TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix.

J Biol Chem. 2000; 275: 31226-31232

[View in Article](#)

- [Scopus \(257\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

9.
 - Qi J.H.
 - Ebrahim Q.
 - Moore N.
 - Murphy G.
 - Claesson-Welsh L.
 - Bond M.
 - et al.

A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2.

Nat Med. 2003; 9: 407-415

[View in Article](#)

- [Scopus \(519\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

10.
 - Amour A.
 - Slocombe P.M.
 - Webster A.
 - Butler M.
 - Knight C.G.
 - Smith B.J.
 - et al.

TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

FEBS Lett. 1998; 435: 39-44

[View in Article](#)

- [Scopus \(537\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

11.
 - Edwards D.R.

TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges.

J Pathol. 2004; 202: 391-394

[View in Article](#)

- [Scopus \(15\)](#)
- [PubMed](#)

- [Crossref](#)
 - [Google Scholar](#)
12. ◦ Ahonen M.
◦ Baker A.H.
◦ Kahari V.M.
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells.
Cancer Res. 1998; 58: 2310-2315
[View in Article](#)
◦ [PubMed](#)
◦ [Google Scholar](#)
13. ◦ Kashiwagi M.
◦ Tortorella M.
◦ Nagase H.
◦ Brew K.
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).
J Biol Chem. 2001; 276: 12501-12504
[View in Article](#)
◦ [Scopus \(418\)](#)
◦ [PubMed](#)
◦ [Crossref](#)
◦ [Google Scholar](#)
14. ◦ Smith M.R.
◦ Kung H.
◦ Durum S.K.
◦ Colburn N.H.
◦ Sun Y.
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells.
Cytokine. 1997; 9: 770-780
[View in Article](#)
◦ [Scopus \(172\)](#)
◦ [PubMed](#)
◦ [Crossref](#)
◦ [Google Scholar](#)
15. ◦ Fitzgerald M.L.
◦ Wang Z.
◦ Park P.W.
◦ Murphy G.
◦ Bernfield M.
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.
J Cell Biol. 2000; 148: 811-824
[View in Article](#)
◦ [Scopus \(339\)](#)
◦ [PubMed](#)
◦ [Crossref](#)
◦ [Google Scholar](#)
16. ◦ Rigg A.S.
◦ Lemoine N.R.
Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo.
Cancer Gene Ther. 2001; 8: 869-878
[View in Article](#)
◦ [Scopus \(70\)](#)
◦ [PubMed](#)
◦ [Crossref](#)

- [Google Scholar](#)
17.
 - Lamfers M.L.
 - Gianni D.
 - Tung C.H.
 - Idema S.
 - Schagen F.H.
 - Carette J.E.
 - et al.

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
Cancer Res. 2005; 65: 9398-9405

[View in Article](#)

 - [Scopus \(46\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
18.
 - Baker A.H.
 - George S.J.
 - Zaltsman A.B.
 - Murphy G.
 - Newby A.C.

Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.
Br J Cancer. 1999; 79: 1347-1355

[View in Article](#)

 - [Scopus \(242\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
19.
 - Reynolds P.N.
 - Nicklin S.A.
 - Kaliberova L.
 - Boatman B.G.
 - Grizzle W.E.
 - Balyasnikova I.V.
 - et al.

Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo.
Nat Biotechnol. 2001; 19: 838-842

[View in Article](#)

 - [Scopus \(209\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
20.
 - Hodge G.
 - Hodge S.
 - Han P.

Increased levels of apoptosis of leukocyte subsets in cultured PBMCs compared to whole blood as shown by Annexin V binding: relevance to cytokine production.
Cytokine. 2000; 12: 1763-1768

[View in Article](#)

 - [Scopus \(46\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
21.
 - Del Poeta G.
 - Venditti A.

- Del Principe M.I.
- Maurillo L.
- Buccisano F.
- Tamburini A.
- et al.

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

Blood. 2003; 101: 2125-2131

[View in Article](#)

- [Scopus \(281\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

22. ◦ Locksley R.M.
- Killeen N.
- Lenardo M.J.

The TNF and TNF receptor superfamilies: integrating mammalian biology.

Cell. 2001; 104: 487-501

[View in Article](#)

- [Scopus \(2863\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

23. ◦ Sprick M.R.
- Weigand M.A.
- Rieser E.
- Rauch C.T.
- Juo P.
- Blenis J.
- et al.

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.

Immunity. 2000; 12: 599-609

[View in Article](#)

- [Scopus \(679\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

24. ◦ Vandenabeele P.
- Declercq W.
- Vanhaesebroeck B.
- Grooten J.
- Fiers W.

Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells.

J Immunol. 1995; 154: 2904-2913

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

25. ◦ Haridas V.
- Darnay B.G.
- Natarajan K.
- Heller R.
- Aggarwal B.B.

Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation.

J Immunol. 1998; 160: 3152-3162

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

26. ◦ Knox P.G.
◦ Milner A.E.
◦ Green N.K.
◦ Eliopoulos A.G.
◦ Young L.S.

Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand.

J Immunol. 2003; 170: 677-685

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

27. ◦ Knox P.G.
◦ Milner A.E.
◦ Green N.K.
◦ Eliopoulos A.G.
◦ Young L.S.

Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand.

J Immunol. 2003; 170: 677-685

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

28. ◦ Zhao Y.
◦ Lu S.
◦ Wu L.
◦ Chai G.
◦ Wang H.
◦ Chen Y.
◦ et al.

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

Mol Cell Biol. 2006; 26: 2782-2790

[View in Article](#)

- [Scopus \(238\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

29. ◦ Bond M.
◦ Murphy G.
◦ Bennett M.R.
◦ Newby A.C.
◦ Baker A.H.

Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.

J Biol Chem. 2002; 277: 13787-13795

[View in Article](#)

- [Scopus \(126\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

30. ◦ Cox G.
◦ Steward W.P.
◦ O'Byrne K.J.

The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.
Thorax. 1999; 54: 169-179

[View in Article](#)

- [Scopus \(50\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

31. ◦ Schutz A.
◦ Schneidenbach D.
◦ Aust G.
◦ Tannapfel A.
◦ Steinert M.
◦ Wittekind C.

Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung.

Tumour Biol. 2002; 23: 179-184

[View in Article](#)

- [Scopus \(57\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

32. ◦ Guedez L.
◦ Stetler-Stevenson W.G.
◦ Wolff L.
◦ Wang J.
◦ Fukushima P.
◦ Mansoor A.
◦ et al.

In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

J Clin Invest. 1998; 102: 2002-2010

[View in Article](#)

- [Scopus \(353\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

33. ◦ Brand K.
◦ Baker A.H.
◦ Perez-Canto A.
◦ Possling A.
◦ Sacharjat M.
◦ Geheeb M.
◦ et al.

Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue.

Cancer Res. 2000; 60: 5723-5730

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

34. ◦ Valente P.
◦ Fassina G.
◦ Melchiori A.
◦ Masiello L.
◦ Cilli M.
◦ Vacca A.
◦ et al.

TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis.

Int J Cancer. 1998; 75: 246-253

[View in Article](#)

- [Scopus \(249\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

35. ◦ Wang M.
◦ Liu Y.E.
◦ Greene J.
◦ Sheng S.
◦ Fuchs A.
◦ Rosen E.M.
◦ et al.

Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4.

Oncogene. 1997; 14: 2767-2774

[View in Article](#)

- [Scopus \(146\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

36. ◦ Ashkenazi A.
◦ Dixit V.M.

Death receptors: signaling and modulation.

Science. 1998; 281: 1305-1308

[View in Article](#)

- [Scopus \(5041\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

37. ◦ Wajant H.

The Fas signaling pathway: more than a paradigm.

Science. 2002; 296: 1635-1636

[View in Article](#)

- [Scopus \(680\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

38. ◦ Itoh N.
◦ Nagata S.

A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen.

J Biol Chem. 1993; 268: 10932-10937

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

39. ◦ Timmer T.
◦ de Vries E.G.
◦ de Jong S.

Fas receptor-mediated apoptosis: a clinical application?.

J Pathol. 2002; 196: 125-134

[View in Article](#)

- [Scopus \(114\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

40. ◦ Heller R.A.
◦ Song K.

- Fan N.
- Chang D.J.

The p70 tumor necrosis factor receptor mediates cytotoxicity.
Cell. 1992; 70: 47-56

[View in Article](#)

- [Scopus \(273\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text PDF](#)
- [Google Scholar](#)

41. ◦ Kelliher M.A.
- Grimm S.
- Ishida Y.
- Kuo F.
- Stanger B.Z.
- Leder P.

The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.
Immunity. 1998; 8: 297-303

[View in Article](#)

- [Scopus \(898\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

42. ◦ Ahonen M.
- Poukkula M.
- Baker A.H.
- Kashiwagi M.
- Nagase H.
- Eriksson J.E.
- et al.

Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors.

Oncogene. 2003; 22: 2121-2134

[View in Article](#)

- [Scopus \(151\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

43. ◦ Belotti D.
- Paganoni P.
- Giavazzi R.

MMP inhibitors: experimental and clinical studies.

Int J Biol Markers. 1999; 14: 232-238

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

44. ◦ Bergers G.
- Javaherian K.
- Lo K.M.
- Folkman J.
- Hanahan D.

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.

Science. 1999; 284: 808-812

[View in Article](#)

- [Scopus \(868\)](#)

- [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
45. ◦ Bloomston M.
 ◦ Shafii A.
 ◦ Zervos E.E.
 ◦ Rosemurgy A.S.
 TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis.
J Surg Res. 2002; 102: 39-44
[View in Article](#)
- [Scopus \(88\)](#)
 - [PubMed](#)
 - [Abstract](#)
 - [Full Text PDF](#)
 - [Google Scholar](#)
46. ◦ Akahane T.
 ◦ Akahane M.
 ◦ Shah A.
 ◦ Connor C.M.
 ◦ Thorgeirsson U.P.
 TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms.
Exp Cell Res. 2004; 301: 158-167
[View in Article](#)
- [Scopus \(81\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
47. ◦ Hornebeck W.
 ◦ Lambert E.
 ◦ Petitfrere E.
 ◦ Bernard P.
 Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.
Biochimie. 2005; 87: 377-383
[View in Article](#)
- [Scopus \(73\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
48. ◦ Ikenaka Y.
 ◦ Yoshiji H.
 ◦ Kuriyama S.
 ◦ Yoshii J.
 ◦ Noguchi R.
 ◦ Tsujinoue H.
 ◦ et al.
 Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model.
Int J Cancer. 2003; 105: 340-346
[View in Article](#)
- [Scopus \(90\)](#)
 - [PubMed](#)
 - [Crossref](#)
 - [Google Scholar](#)
49. ◦ Feldman A.L.

- Stetler-Stevenson W.G.
- Costouros N.G.
- Knezevic V.
- Baibakov G.
- Alexander Jr., H.R.
- et al.

Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.

Cancer Res. 2004; 64: 4481-4486

[View in Article](#)

- [Scopus \(32\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

50. ◦ Stetler-Stevenson W.G.
- Seo D.W.

TIMP-2: an endogenous inhibitor of angiogenesis.

Trends Mol Med. 2005; 11: 97-103

[View in Article](#)

- [Scopus \(133\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

51. ◦ Anand-Apte B.
- Pepper M.S.
 - Voest E.
 - Montesano R.
 - Olsen B.
 - Murphy G.
 - et al.

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.

Invest Ophthalmol Vis Sci. 1997; 38: 817-823

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

52. ◦ Spurbeck W.W.
- Ng C.Y.
 - Strom T.S.
 - Vanin E.F.
 - Davidoff A.M.

Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model.

Blood. 2002; 100: 3361-3368

[View in Article](#)

- [Scopus \(90\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

53. ◦ Yu X.F.
- Yang C.
 - Liang L.H.
 - Liu B.
 - Zhou B.
 - Li B.
 - et al.

Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3.

Leukemia. 2006; 20: 1-8

[View in Article](#)

- [Scopus \(15\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

54. ◦ Apte S.S.
◦ Olsen B.R.
◦ Murphy G.

The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family.

J Biol Chem. 1995; 270: 14313-14318

[View in Article](#)

- [Scopus \(279\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

55. ◦ Leco K.J.
◦ Khokha R.
◦ Pavloff N.
◦ Hawkes S.P.
◦ Edwards D.R.

Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues.

J Biol Chem. 1994; 269: 9352-9360

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

Article Info

Publication History

Accepted: June 11, 2006

Received in revised form: May 7, 2006

Received: March 6, 2006

Identification

DOI: <https://doi.org/10.1016/j.lungcan.2006.06.006>

Copyright

© 2006 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Linked Article

- [Corrigendum to “In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2” \[Lung Cancer 53 \(3\) \(September 2006\) 273–284\]](#)
Lung Cancer Vol. 101
 - [Preview](#)
The authors regret that Fig. 8 was noted to inadvertently contain duplicate panels that were labeled as different treatment groups. A correct panel is provided: Effect of AdCMVTIMP3 on apoptosis by TUNEL assay. (1-a) PBS, (1-b) AdCMVLuc, (1-c) AdCMVTIMP-1, (1-d) AdCMVTIMP-2, (1-e) AdCMVTIMP-3.
 - [Full-Text](#)
 - [PDF](#)

Related Articles

[Hide Caption](#)[Download](#)[See figure in Article](#)
[Toggle Thumbstrip](#)

- [Download Hi-res image](#)
- [Download .PPT](#)



[Home](#)

ARTICLES AND ISSUES

[Articles in Press](#)

[Current Issue](#)

[List of Issues](#)

FOR AUTHORS

[About Open Access](#)

[Author Information](#)

[Permissions](#)

[Researcher Academy](#)

[Submit a Manuscript](#)

JOURNAL INFO

[About Open Access](#)

[About the Journal](#)

[Abstracting/Indexing](#)

[Advertising Information](#)

[Career Opportunities](#)

[Contact Information](#)

[Editorial Board](#)

[Pricing](#)

[New Content Alerts](#)

SUBSCRIBE

SOCIETY INFO

[International Lung Cancer Consortium \(ILCCO\)](#)

[European Thoracic Oncology Platform \(ETOP\)](#)

[British Thoracic Oncology Group \(BTOG\)](#)

MORE PERIODICALS

[Find a Periodical](#)

[Go to Product Catalog](#)

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie Preference Center](#) for this site.

Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

- [Privacy Policy](#)
- [Terms and Conditions](#)
- [Accessibility](#)
- [Help & Contact](#)